Mylan's EpiPen Boosted as FDA Sees Holes in Teva Application

  • Teva expects its injection will be `significantly delayed'
  • Israel drugmaker will submit response to U.S. agency

Mylan NV may be able to curtail a decline in future sales of its EpiPen allergy-reaction injector after the U.S. Food and Drug Administration identified “major deficiencies” in an application for a competing generic version from Teva Pharmaceutical Industries Ltd.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.